TY - JOUR
T1 - Development of an automated immunoassay for advanced glycosylation end products in human serum
AU - Lin, Chuai Yu
AU - Chen, Chuan Sern
AU - Shieh, Ming Song
AU - Wu, Chih Hsiung
AU - Lee, Horng Mo
N1 - Funding Information:
HML was supported by grants NSC-89-2320-B-038- 009, and NSC-90-2320-B038-030 from the National Science Council, Taipei, Taiwan. The authors wish to thank Hsiao-Jen Lu, and Shu-Ting Tsai for their skilled technical assistance.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1%, and the mean recovery rate was 98.6%. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.
AB - Objective: Nonenzymatic reaction of protein and carbohydrate produce a series of brown fluorescent advanced glycosylation end products (AGEs). However, a convenient and rapid assay for serum AGEs level is currently unavailable. Methods: We raised AGEs-specific polyclonal antibodies, which were used to develop a fully automated, noncompetitive, homogeneous, light-scattering immunoassay for serum AGEs. Results: The assay requires a sample volume of 2 μL and takes a reaction time of 2 min. The coefficient of variation range from 1.8 to 6.1%, and the mean recovery rate was 98.6%. Comparative analysis shows moderate correlation with competitive ELISA (r = 0.8209, n = 52). The mean ± SD concentration of AGEs in young and in older healthy subjects were 4.6 ± 1.5 (n = 39) and 4.9 ± 1.4 (n = 40), respectively. The level of AGEs was significantly higher in serum from patients with type II DM 7.8 ± 4.8 (n = 89) than that from the normal subjects (p <0.05). Conclusions: The automatic immunoassay for AGEs is appropriate for clinical use.
KW - Advanced glycosylation end products
KW - Competitive ELISA
KW - Diabetes mellitus
KW - End stage renal diseases
KW - Light-scattering immunoassay
UR - http://www.scopus.com/inward/record.url?scp=0036017350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036017350&partnerID=8YFLogxK
U2 - 10.1016/S0009-9120(02)00302-8
DO - 10.1016/S0009-9120(02)00302-8
M3 - Article
C2 - 12074826
AN - SCOPUS:0036017350
SN - 0009-9120
VL - 35
SP - 189
EP - 195
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 3
ER -
